Additional file 1

Cost-effectiveness model and data inputs

Contents

1. Model structure .................................................................................................................... 1
2. Transition probabilities ........................................................................................................ 1
   2.1 Ischaemic heart disease .............................................................................................. 1
   2.2 Stroke ............................................................................................................................ 2
   2.3 Background mortality ................................................................................................. 2
   2.4 Disease trends ............................................................................................................ 2
3. Quality of life adjustment .................................................................................................... 2
4. Costs of disease treatment .................................................................................................. 3
5. Uncertainty analysis .......................................................................................................... 4

References ................................................................................................................................ 5
1. Model structure

The ischaemic heart disease (IHD) and stroke prevention model is a deterministic Markov model [1] that provides information on health and health care costs over the lifetime of the Australian population (or population sub-groups). The model includes four mutually exclusive health states, with transition between states based on age, sex and multivariate risk-adjusted transition probabilities (Figure 1).

Each five-year age and sex cohort initially begins in the *Alive* state before any incident IHD event (hospitalised angina or acute myocardial infarction) or stroke event (cerebral infarction or intracerebral haemorrhage). Over time, proportions of the cohort may move into an *Alive* state following an IHD event or an *Alive* state following a stroke event, with incident events divided into those that are fatal within the first year and those that survive the first year. Survivors of a first-ever event are at increased risk of death from IHD or Stroke, but may also die from other causes. Transitions are simulated annually until all of the cohort population are dead or have reached 100 years of age.

Although we do not explicitly model ischaemic and haemorrhagic sub-types of stroke as different states, differential rates of incidence and case fatality for either type of stroke event that are fatal within the first year, are taken into account in the transition probabilities.

![Figure 1 Markov model for simulating IHD and stroke events](image)

2. Transition probabilities

2.1 Ischaemic heart disease

The incidence of 28-day survivors of first ever IHD is derived from recorded cases of acute myocardial infarction and unstable angina in the National Hospital Morbidity Database [2]. We then determine the incidence rate in those without previous IHD or stroke, using relative risks of incident IHD in
those with stroke form the Busselton study [3, 4] and prevalence of stroke in those without previous IHD from AusDiab [5].

Differential rates of case fatality from AMI and angina in the first 28 days are taken into account using in-hospital 28-day case fatality from the National Hospital Morbidity Database [2] and estimates of pre-hospital case fatality from the Perth MONICA study [6]. We calculate case fatality from IHD as the excess mortality in prevalent IHD survivors compared to total population mortality risks using the Western Australia Linked Hospital Database [7, 8].

2.2 Stroke

The incidence of 28-day survivors of first-ever stroke is derived from the population-based NEMESIS study [9] and Australian hospital separations data [2]. NEMESIS study incidence is scaled to a national level incidence using the ratio of hospital admissions in the NEMESIS study postcode areas at the time of the NEMESIS study, to hospital admissions Australia-wide in 2003. We adjust the stroke incidence rate to reflect the incidence rate in those without either previous IHD or stroke, using relative risks of incident stroke in those with IHD from the Busselton study [3, 4] and prevalence of IHD in those without previous stroke from AusDiab [5].

We derive separate rates of case fatality from ischaemic and haemorrhagic stroke events within the first 28 days from the NEMESIS study [9] and case fatality from stroke in 28-day survivors using the Western Australia Linked Hospital Database [8, 10].

2.3 Background mortality

Mortality from all causes other than IHD and stroke is calculated from the total number of deaths recorded by the Australian Bureau of Statistics [11] excluding deaths attributed to IHD or Stroke in the 2003 Australian Burden of Disease study [7], projected to 2008 using projections from Australian mortality data [12].

2.4 Disease trends

Future trends in IHD and stroke incidence and case fatality are based on projections made by Begg et al. [12] from observed Australian mortality between 1979 and 2003. We assume that 58% of the trend is attributable to declining incidence (i.e. due to changes in disease risk factors) and 42% to declining case fatality (i.e. due to changes in survival of those with disease) [13]. The trends are applied for the first 15 years with rates assumed to remain constant thereafter.

3. Quality of life adjustment

At each cycle of the Markov model, we calculate years of life lived within each health state, adjusting for time spent in ill health due to IHD, stroke and all other causes, to determine health gain in quality-adjusted life years (QALYs). We correct utility weights for angina, congestive heart failure, and myocardial infarction, from the Beaver dam study [14], using US population norms for background quality of life [15] (Table 1). For stroke, we correct utility weights derived in the NEMESIS
stroke study for background quality of life using AQoL population norms [16]. Average population utility weights are derived from AQoL measures for the Australian population [17] (Figure 2).

Table 1 QALY utility weights and DALY disability weights for modelled heart diseases and ulcer/GI bleed (NB. 0 represents the worst possible health state and 1 represents normal health).

<table>
<thead>
<tr>
<th>Disease</th>
<th>QALY utility weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>Angina</td>
<td>0.904 [14, 15]</td>
</tr>
<tr>
<td>Congestive heart failure</td>
<td>0.863 [14, 15]</td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>0.877 [14, 15]</td>
</tr>
<tr>
<td>Stroke</td>
<td>0.76 [16]</td>
</tr>
</tbody>
</table>

NB. Beaver dam study utility weights (Quality of Well-being index) corrected for ‘background disability’ using US population norms (Quality of Well-being index) [15], combined multiplicatively, assuming the ‘average’ age for each condition is the same as in Australia [7].

Figure 2 Average quality of life for Australians derived using the Assessment of Quality of Life (AQoL) tool [17] (NB. 0 represents the worst possible health state and 1 represents normal health).

4. Costs of disease treatment

Costs of treating IHD are determined separately for the first and subsequent years of treatment. First year costs are derived from a Victorian Government study [18] of hospital inpatient costs for IHD treatment and rehabilitation admissions, and from a study by Lim [19] of government and patient out-of-hospital costs for consultations, drugs and diagnostic procedures, and Medicare rebates for private-sector consultations and procedures. Three-quarters of first-year costs are assumed to recur in subsequent years. We derive the direct costs of treating stroke in the first year after an event and annual costs of treatment in subsequent years from the NEMESIS study of stroke costs [20]. We adjust all costs to Australian dollars in the year 2008 using health system deflators [21].
5. Uncertainty analysis

Ninety-five percent uncertainty intervals are derived for all cost and health outcome measures by Monte Carlo analysis (2000 iterations) using the Excel Add-In program @Risk (Palisade, Version 4.5). Table 2 shows the uncertainty distributions, sources and assumptions for the model input parameters.

Table 2 Model input parameters and their uncertainty distributions.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
<th>Uncertainty distribution</th>
<th>Sources and assumptions</th>
</tr>
</thead>
<tbody>
<tr>
<td>RR of IHD with treatment</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– Statin</td>
<td>0.70 (0.05)</td>
<td>Normal</td>
<td>Meta-analyses of primary prevention trials [22-24]</td>
</tr>
<tr>
<td>– Diuretic</td>
<td>0.86 (0.06)</td>
<td>Normal</td>
<td>Meta-analyses of primary prevention trials [22-24]</td>
</tr>
<tr>
<td>– Calcium channel blocker</td>
<td>0.85 (0.04)</td>
<td>Normal</td>
<td>Meta-analyses of primary prevention trials [22-24]</td>
</tr>
<tr>
<td>– ACE inhibitor</td>
<td>0.83 (0.03)</td>
<td>Normal</td>
<td>Meta-analyses of primary prevention trials [22-24]</td>
</tr>
<tr>
<td>– Beta-blocker</td>
<td>0.78 (0.03)</td>
<td>Normal</td>
<td>Meta-analyses of primary prevention trials [22-24]</td>
</tr>
<tr>
<td>RR of stroke with treatment</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– Statin</td>
<td>0.81 (0.06)</td>
<td>Normal</td>
<td>Meta-analyses of primary prevention trials [22-24]</td>
</tr>
<tr>
<td>– Diuretic</td>
<td>0.62 (0.05)</td>
<td>Normal</td>
<td>Meta-analyses of primary prevention trials [22-24]</td>
</tr>
<tr>
<td>– Calcium channel blocker</td>
<td>0.66 (0.04)</td>
<td>Normal</td>
<td>Meta-analyses of primary prevention trials [22-24]</td>
</tr>
<tr>
<td>– ACE inhibitor</td>
<td>0.78 (0.07)</td>
<td>Normal</td>
<td>Meta-analyses of primary prevention trials [22-24]</td>
</tr>
<tr>
<td>– Beta-blocker</td>
<td>0.70 (0.04)</td>
<td>Normal</td>
<td>Meta-analyses of primary prevention trials [22-24]</td>
</tr>
<tr>
<td>First year discontinuation of drug therapy</td>
<td>40% (8%)</td>
<td>Beta</td>
<td>Estimate from Australian data on discontinuation of statin and blood pressure-lowering drugs [25, 26]. Standard error assumed to be 20% of point estimate.</td>
</tr>
<tr>
<td>RR IHD in stroke</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– Men</td>
<td>2.64 (0.07)</td>
<td>Normal</td>
<td>Busselton study [3, 4]</td>
</tr>
<tr>
<td>– Women</td>
<td>2.85 (0.04)</td>
<td>Normal</td>
<td>Busselton study [3, 4]</td>
</tr>
<tr>
<td>Proportion of GPs participating in primary prevention program</td>
<td>65% (6.5%)</td>
<td>Beta</td>
<td>Estimate from GP and GP practice participation in the Practice Incentives Program scheme [27].</td>
</tr>
<tr>
<td>IHD</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– First year</td>
<td>$12,921</td>
<td>Uniform</td>
<td>Lim [19]. Uniform distribution assumed to vary by ±25% around mean.</td>
</tr>
<tr>
<td>– Subsequent years</td>
<td>$4,539</td>
<td>Uniform</td>
<td>Lim [19]. Uniform distribution assumed to vary by ±25% around mean.</td>
</tr>
<tr>
<td>Stroke</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– First year</td>
<td>$23,581</td>
<td>Uniform</td>
<td>Lim [19]. Uniform distribution assumed to vary by ±25% around mean.</td>
</tr>
<tr>
<td>– Subsequent years</td>
<td>$3,201</td>
<td>Uniform</td>
<td>Lim [19]. Uniform distribution assumed to vary by ±25% around mean.</td>
</tr>
<tr>
<td>Long GP visit [28]</td>
<td>$63.75</td>
<td>–</td>
<td>One visit in Year 1.</td>
</tr>
<tr>
<td>Short GP visit [28]</td>
<td>$33.55</td>
<td>–</td>
<td>Two visits in Year 1 (with BP-lowering drugs) and two visits in Year 2+.</td>
</tr>
<tr>
<td>Blood test (MBS Item 66512) [28]</td>
<td>$17.80</td>
<td>–</td>
<td>One test in Year 1 (with lipid-lowering drugs) or three tests in Year 1 (with BP-lowering drugs), and two tests in Year 2+.</td>
</tr>
<tr>
<td>Annual cost of low-dose diuretic therapy</td>
<td>$69.35</td>
<td>–</td>
<td>Average annual cost for the standard daily dose [29] of hydrochlorothiazide, chlorothalidone and indapamide, weighted by scripts provided in 2008 [30].</td>
</tr>
<tr>
<td>Annual cost of beta-blocker therapy</td>
<td>$105.85</td>
<td>–</td>
<td>Average annual cost for the standard daily dose [29] of atenolol, metoprolol, propranolol, oxprenolol and pindolol, weighted by scripts provided in 2008 [30].</td>
</tr>
</tbody>
</table>
Annual cost of calcium channel blocker therapy $219.00 – Average annual cost for the standard daily dose [29] of verapamil, amlodipine (maleate), nifedipine, felodipine, amlodipine (besylate) and lercanidipine, weighted by scripts provided in 2008 [30].

Annual cost of ACE inhibitor therapy $211.70 – Average annual cost for the standard daily dose [29] of captopril, fosinopril, enalapril, ramipril, quinapril, lisinopril,trandolopril and perindopril, weighted by scripts provided in 2008 [30].

Annual cost of aspirin therapy $40.15 – Average annual cost, assuming 50% of aspirin purchased by prescription and 50% over-the-counter [30-32].

Annual cost of statin therapy $686.20 – Average annual cost for the standard daily dose [29] of fluvastatin, simvastatin, atorvastatin, pravastatin and rosuvastatin, weighted by scripts provided in 2008 [30].

Annual cost of statin therapy in New Zealand $18.25 – Average annual cost of simvastatin (40mg/day) in New Zealand [33].

Annual cost of current practice lipid-lowering therapy $682.55 – Average annual cost from actual PBS expenditure on lipid-lowering drugs in 2008 [30].

Annual cost of current practice blood pressure-lowering therapy $686.20 – Average annual cost from actual PBS expenditure on blood pressure-lowering drugs in 2008 [30]. Mix of diuretics, beta-blockers, calcium channel blockers and ACE inhibitors based on BEACH general practice data [34].

NB. All costs adjusted to 2008 Australian dollars using Australian health price deflators [21], consumer price index [35] and/or purchasing power parities [36] where relevant.

References


8. Department of Health: *Western Australian Data Linkage*. In *Book Western Australian Data Linkage* (Editor ed.^eds.). City: Department of Health (Western Australia), The University of Western Australia, Curtin University of Technology, Telethon Institute of Child Health Research.


31. MIMS Online: [www.mimsonline.com.au]